Juniper (telehealth company)

Services

Juniper delivers weight-management services through an online health assessment followed by a clinician review and consultation. Eligible patients may be prescribed TGA-approved or other regulator-approved weight-loss medications, including liraglutide, semaglutide and tirzepatide, supplied via partner pharmacies. In Australia, Juniper does not publicly advertise any medicines by name before consultation due to advertising restrictions.

Relationship with Eucalyptus Health

Juniper is one of several healthcare brands under Eucalyptus Health, alongside Pilot, Kin, Software and Compound. By 2025, the United Kingdom had become Eucalyptus Health's largest market.

During a period of medication shortage, Eucalyptus temporarily paused new Juniper memberships in the UK to prioritise existing patients. In March 2025, Eucalyptus reported A$200 million in revenue over the preceding 18 months from weight-loss services, with revenue rising 55% year-on-year to A$120.9 million. In May 2025, Eucalyptus entered early discussions for a funding round of A$100–150 million, targeting a valuation exceeding A$1 billion.

Regulatory scrutiny

Juniper's growth and marketing have drawn public, professional and regulatory attention globally. From 2023, it was cited in reports examining telehealth-based weight-loss regulation in Australia. The RACGP and medical regulators raised concerns about prescribing models using asynchronous or questionnaire-based assessments for injectable weight-loss medications. The TGA assessed whether online advertising by Juniper could indirectly promote prescription-only medicines, requesting removal of thousands of unlawful advertisements between 2022 and 2024.

In July 2023, the TGA investigated whether Juniper's emails about Ozempic availability constituted unlawful advertising. Through 2024, the TGA proposed removing GLP-1 medicines from pharmacy compounding exemptions, warning that compounded products lacked safety and quality requirements. The Australian government subsequently banned pharmacy compounding of GLP-1 medicines. In November 2024, regulators examined whether Juniper's advertising indirectly promoted prescription-only medicines, with clinicians and eating-disorder advocates calling for stricter oversight.

Technology and AI

In July 2025, Eucalyptus Health teamed up with Amigo, an AI healthcare platform, to bring AI-powered health agents into its telehealth offerings, including an assistant for the Juniper weight management clinic. Juniper launched an AI chatbot called June that offers automated advice on nutrition, medication, and weight-loss plateaus. Mental-health and psychology experts warned that strong safeguards were needed for AI in weight management to protect vulnerable patients, such as those with a history of eating disorders.

Did You Know?

• In January 2024, Eucalyptus appointed former Australian deputy chief medical officer Nick Coatsworth as a clinical governance adviser following scrutiny over prescribing of compounded semaglutide.